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D23focuses on RHF in the setting of PAH, the committee also
wants to emphasizes that RV function is also a strong
predictor of outcomes in patients with left heart failure,
advanced lung disease, and congenital heart disease (20).
Deﬁnition of the Right Heart Failure Syndrome
RHF in patients with PAH can be deﬁned as a complex
clinical syndrome due to suboptimal delivery of blood and/or
elevated systemic venous pressure at rest or exercise as
a consequence of elevated RV afterload.
The cardinal clinical manifestations of RHF are exercise
limitation and ﬂuid retention. Exercise limitation is the
earliest symptom of RHF and is a strong predictor of
survival in patients with PAH (8,14,21). Exercise limitation
is related to a decrease in ﬂow reserve during exercise
(decreased peak cardiac index) (22–24). In addition,
a reduction in peripheral blood ﬂow can increase lactate
production, further contributing to muscle fatigue and
exercise limitation. Supraventricular tachycardia, which can
occur in approximately 12% of patients with PAH or
inoperable thromboembolic pulmonary hypertension, can
also lead to clinical deterioration and reduced exercise
capacity (25). Syncope, a less common symptom of PAH,
often indicates severe limitations in ﬂow reserve. As in left-
sided heart failure, RHF can also lead to chronic kidney
disease and hyponatremia (26). Shah et al. (27) showed that
chronic kidney disease in patients with PAH is associated
with increased right atrial pressure and a higher likelihood of
death or transplantation. Similarly, acute kidney injury has
also been associated with worse outcomes after acute RHF
(28). Although congestive hepatopathy is often observed in
patients with RHF and PAH, cirrhosis is a late complication
of severe RHF. In patients with worsening hypoxemia and
PAH, right-to-left shunting through a patent foramen ovale
must be considered.
Patients with PAH may also present with acute heart
failure. Recent studies have shown that the short-term
mortality in patients with PAH and acute RHF may be as
high as 40% in patients who require admission to the hospital
(29–32). Although the majority of patients with acute RHF
are admitted with congestive symptoms requiring diuretic
therapy, a smaller proportion of patients will have low–cardiac
output syndrome requiring inotropic or vasopressor support
(29,30). Although the most common cause of death in
patients with PAH is progressive RHF, sudden and unex-
pected death may also occur (33). In a study by Hoeper et al.
(33), sudden death explained 17% of cardiopulmonary arrest
for which resuscitation was attempted. Among all patients
who had cardiopulmonary arrest (not just those with sudden
death), the initial electrocardiogram at the time of cardio-
pulmonary resuscitation showed bradycardia in 45%, elec-
tromechanical dissociation in 28%, asystole in 15%,
ventricular ﬁbrillation in 8%, and other rhythms in 4% (33).
In patients with chronic left heart failure, heart failure is
usually classiﬁed into 4 stages of development: at risk for heartfailure (stage A), “asymptomatic”
heart dysfunction (stage B), symp-
tomatic heart failure (stage C), and
end-stage heart failure (stage D)
(34). This classiﬁcation could
potentially be applied to patients
with RHF, with the caveat that
the majority of patients with
advanced RHF (stage D) have
the ability to reverse remodel
after lung transplantation. Also
importantly, although we often
consider the right ventricle and
the left ventricle as separate en-
tities, this distinction is some-
what artiﬁcial, because both
ventricles are interconnected th-
rough the interventricular sep-
tum, shared myoﬁbers, and the
pericardium. Because of ventric-
ular interdependence, patients
with RHF will often have relax-
ation abnormalities of the left
ventricle and, in severe cases,
even left ventricular systolic
dysfunction (2,20,35). Recent stu-
dies have also emphasized electro-
physiological remodeling in the left ventricle in patients
with PAH (36).Pathobiology of Right Heart Failure Syndrome in
Pulmonary Arterial Hypertension
The continuum of RV remodeling in PAH. RV adap-
tation and ventricular remodeling in PAH is a complex
process that depends not only on the severity of pulmonary
vascular disease but also on the interplay between neuro-
hormonal activation, coronary perfusion, and myocardial
metabolism (Fig. 1) (6,20,37–45). Other factors that may
inﬂuence RV adaptation include the rate and time of onset
of pulmonary hypertension, its underlying etiology, and,
although not yet well deﬁned, genetic and epigenetic
factors.
Although ventricular remodeling in PAH represents
a continuum, experimental studies often differentiate 2
patterns of ventricular remodeling on the basis of morpho-
metric and molecular characteristics: adaptive and malad-
aptive remodeling (Table 1). Adaptive remodeling is
characterized by more concentric remodeling (higher mass-
to-volume ratio) and preserved systolic and diastolic func-
tion (e.g., ventricular remodeling observed in patients with
Eisenmenger syndrome), whereas maladaptive remodeling is
associated with more eccentric hypertrophy and worse
systolic and diastolic function (e.g., remodeling observed in
patients with PAH associated with connective tissue disease
or idiopathic PAH) (9,46). Tricuspid regurgitation, which is
Figure 1 Pathophysiology of RV Dysfunction in PAH
Increased right ventricular (RV) wall stress, neurohormonal activation, inﬂammation, and altered bioenergetics contribute to RV remodeling in pulmonary arterial hypertension
(PAH). Adaptive remodeling is associated with minimally altered ventriculoarterial coupling. Progressive RV dilation with maladaptive remodeling further contributes to RV stress.
Adapted, with permission, from Champion et al. (5), Benza et al. (8), and Rudski et al. (99).
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D24often secondary to annular dilation, may also lead to ad-
verse ventricular remodeling and decreased ﬂow reserve.
Right-to-left shunting through a patent foramen ovale is
also observed more frequently in patients with maladaptive
remodeling and more severe RHF (47). Recent studies also
suggest that RV dyssynchrony is a marker of maladaptive
remodeling and more severe dysfunction (48–54). In PAH,
the RV free wall is still contracting while the left ventricle is
already in its early diastolic phase, leading to late systolic
leftward septal movement (55). Because myocytes under
mechanical stress prolong their contraction time and action
potential duration, right-to-left ventricular dyssynchrony
will increase in the failing right ventricle with increased wall
stress, explaining why measures of dyssynchrony are asso-
ciated with prognosis.
When comparing ventricular remodeling with pressure
overload, several differences emerge between the right and left
ventricles. First, ventricular enlargement occurs much earlier
in the course of PAH compared with the pressure-overloaded
left ventricle (e.g., in systemic hypertension or aortic stenosis).
Mechanically, this can be partially explained by the fact thatRV wall stress is greater for a comparable pressure increase
because of the smaller thickness of the right ventricle. Second,
ﬁbrosis is much less extensive in patients with RV pressure
overload (often <10% of ventricular volume) and often
limited to the RV-septal insertion points compared with
myocardial ﬁbrosis observed in patients with aortic stenosis or
severe systemic hypertension (56–59). This explains why the
majority of patients with severe RHF recover their ventricular
function after lung transplantation, even if right ventricular
ejection fraction (RVEF) is severely reduced at the time of
transplantation (60–63). Identifying which patients would
not recover right heart function after lung transplantation
alone and therefore would beneﬁt from heart-lung trans-
plantation remains a subject of ongoing investigation (64).
The concept of ventriculoarterial coupling and the
cardiopulmonary unit in PAH. Recent focus in PAH
research has shifted from looking at the pulmonary vascu-
lature and the right heart as separate entities to analyzing the
cardiopulmonary unit as a system (5). This is valid not only
from the physiological perspective but also from a thera-
peutic aspect. Several studies have shown that RV adaptation
Table 1 Continuum of Adaptive Versus Maladaptive Remodeling of the Right Ventricle
Characteristic Adaptive Remodeling Maladaptive Remodeling
Remodeling
RV size Normal size to mild dilation RV enlargement
Mass/volume ratio Higher Lower
Function
VA coupling Usually preserved or mildly decreased Lower
RVEF at rest Normal to mildly decreased Decreased
CPET Usually better preserved exercise
capacity and ventilatory efﬁciency
Decreased exercise capacity and
increased ventilatory inefﬁciency
Ventricular/ﬂow reserve Probably decreased early Decreased
BNP or NT-BNP Normal Elevated
Perfusion Normal or mildly impaired Decreased
Metabolism Normal glucose uptake Increased glucose uptake
Molecular (selected)
Micro-RNA 133a Normal Decreased
Apelin Increased Severely reduced
Insulin-like growth factor-1 Increased No increase
Vascular endothelial growth factor Increased Normal/reduced
Hexokinase-1 Decreased Increased
Alcohol dehydrogenase-7 Normal Decreased
Most of the molecular data are based on experimental studies. Ventricular reserve refers to either the contractile response of the right ventricle or
the dynamic change in diastolic RV end-diastolic pressures during exercise or pharmacological stress.
BNP ¼ B-type natriuretic peptide; CPET ¼ cardiopulmonary exercise testing; NT-BNP ¼ N-terminal B-type natriuretic peptide; RNA ¼ ribonucleic
acid; RV ¼ right ventricular; RVEF ¼ right ventricular ejection fraction; VA ¼ ventriculoarterial.
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D25to PAH depends on the right ventricle’s ability to increase its
contractility in response to the increased afterload (43,65).
“Ventriculoarterial coupling” speciﬁcally refers to the rela-
tionship between ventricular contractility and afterload
(Fig. 2). Its most objective metric is the ratio between
ventricular elastance and arterial elastance. Although the
idea is based mainly on research involving the left ventricle,
it is assumed that the normal ratio of ventricular to arterial
elastance for the right ventricle is also between 1.5 and 2.0,Figure 2 Describing Right Ventricular Function
(A) Pressure-volume relation, illustrating the concepts of ventricular elastance (Ees), arter
Ees. (B) Pump function graph, illustrating that when baseline pulmonary vascular resistanc
at lower baseline PVR, pressure is more affected.corresponding to an optimal balance between RV mechan-
ical work and oxygen consumption (5,43,66). Kuehne et al.
previously showed that chronic RV pressure overload in PAH
was associated with reduced RV pump function despite
enhanced RVmyocardial contractility. Using ventriculoarterial
measures, recent studies have also conﬁrmed worse ven-
triculoarterial coupling in patients with scleroderma-associated
PAH compared with those with afterload-matched idiopathic
PAH (67).ial elastance (Ea), and the maximal isovolumic pressure used to estimate single-beat
e (PVR) is high, a decrease in PVR mainly causes an increase in stroke volume, while
Table 2 Measures of Ventricular and Pulmonary Load
Component of Load Equation or Deﬁnition Comment
PVR PVR ¼ TPG/CO Most commonly used clinical measure of resistive load
PAC PAC ¼ SV/PP Most commonly used clinical measure of pulsatile load
Ea Ea ¼ RVESP/SV Common measure of load used in pressure-volume loop analysis
Pulmonary impedance Fourier transformation yields impedance and
phase according to harmonics
Used in experimental and research settings; cannot be summarized by a
single number
DPPG DPPG ¼ DPAP  mean PCWP New markers to assess out-of-proportion heart failure with left heart disease
Mean pulmonary arterial distensibility (Areasystole  Areadiastole)/Areasystole Assessed with MRI; may be useful in detecting early PH
Mean PAP-CO slope Slope of mean PAP to CO relationship or main
slope of TPG-CO relationship
The slope represents a more dynamic concept of resistance to ﬂow; may
be a more physiological way to deﬁne exercise-induced PH
RV afterload Estimated by RV wall stress: RVESWS ¼
(0.5  RVSP  rRVES)/RVES wall thickness
Simpliﬁed formula, as RV geometry is more difﬁcult to assess
PVR can be indexed to BSA. Usually PAC is not indexed, because it represents a measure of ﬂow and pressure.
CO ¼ cardiac output; DPAP ¼ diastolic pulmonary arterial pressure; DPPG ¼ diastolic pulmonary pressure gradient; Ea ¼ pulmonary arterial elastance; MRI ¼ magnetic resonance imaging;
PAC ¼ pulmonary arterial capacitance; PAP ¼ pulmonary arterial pressure; PCWP ¼ pulmonary capillary wedge pressure; PH ¼ pulmonary hypertension; PP ¼ pulmonary pressure; PVR ¼ pulmonary
vascular resistance; rRVES ¼ right ventricular end-systolic radius; RV ¼ right ventricular; RVES ¼ right ventricular end-systolic; RVESP ¼ right ventricular end-systolic pressure; RVESWS ¼ right ventricular
end-systolic wall stress; RVSP ¼ right ventricular systolic pressure; SV ¼ stroke volume; TPG ¼ transpulmonary gradient.
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D26Clinically, RV afterload is estimated using simple
measures of load such as arterial elastance, pulmonary
vascular resistance, and pulmonary arterial compliance
(Table 2). Arterial elastance is the metric of afterload used
during pressure-volume loop analysis, while pulmonary
vascular resistance and pulmonary arterial compliance are
used to describe the resistive and pulsatile load of the
pulmonary circulation. The resistive and pulsatile compo-
nents of pulmonary load are also useful to describe the work
of the right ventricle. Recent studies have found that theFigure 3 Molecular Pathways Involved in RV Remodeling in PAH
The ﬁgure outlines the importance of cardiomyocyte remodeling involving altered metabo
metabolism, and endothelial reticulum stress. PAH ¼ pulmonary arterial hypertension; Rsteady or resistive component accounts for approximately
77% of total hydraulic RV power and that the remaining
23% is used for the pulsatile component (68). This relatively
constant distribution follows from the unique properties of
the pulmonary circulation compared with the systemic
circulation. In contrast to the systemic circulation, in the
pulmonary circulation, resistance and compliance are
inversely related to each other over time and after therapy
(Fig. 3) (69,70). This is because the resistive vessels in the
pulmonary circulation also contribute to the compliance oflism, increased reactive oxygen species (ROS) production, decreased oxidative
V ¼ right ventricular.
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D27the system (71). Recent studies have showed, however, that
elevated pulmonary capillary wedge pressure can decrease the
resistance-compliance time constant in the pulmonary
system, thus enhancing net RV afterload by elevating
pulsatile, relative to resistive, load (72).
Although the previously mentioned indexes of afterload
are clinically useful, a more physiological deﬁnition of RV
afterload would need to take into account all factors that
contribute to total myocardial wall stress (or tension) during
systole, such as ventricular pressure, chamber enlargement,
wall thickness, and ventricular geometry. Moreover, tricuspid
regurgitation and right-to-left shunting (i.e., through
a patent foramen ovale, septal defect, or atrial septostomy)
can also decrease afterload by offering an alternative, less
resistive path (73–75). More comprehensive models of
afterload may better predict the course of RHF. Research
groups are currently working on developing biophysical
models linking local cardiac myoﬁber mechanics to global
cardiovascular system dynamics and adaptation are currently
being developed. These models provide novel insights into
the mechanisms of cardiac adaptation to PAH (76,77).
Similarly, pre-load can be deﬁned as the combination of the
factors that contribute to passive end-diastolic ventricular
wall stress (or tension). Optimal pre-load is the pre-load that
leads to maximal cardiac output without causing signiﬁcant
systemic congestion or renal impairment (27). This is espe-
cially important in tailoring pre-load in patients with acute
RHF and is discussed in the section on management.
Molecular insights into RV remodeling and failure. In
recent reviews, the different pathways involved in remodel-
ing of the pressure-overloaded right ventricle have been
summarized (40,78). The different animal models used to
study the pressure-overloaded right ventricle were recently
reviewed by Guihaire et al. (79). More recent investigations
are using induced pluripotent stem cells for screening of
novel molecules in PAH and RHF; proof-of-concept results
for these novel strategies should be available within the next
few years. Although genetic studies are identifying novelTable 3
Comparative Remodeling of Right Ventricle and Pulmonary C
Main Cellular and Interstitial Features (19–22)
Pulmonary Circulation
Differences
Cellular changes Resistance to apoptosis and aberrant prolif
(PAECs and PASMCs), hyperplasia, and m
Microcirculation changes Dysregulated angiogenesis
Similarities
Extracellular matrix Increased interstitial ﬁbrosis
Mitochondrial remodeling Decreased number abnormal shape and siz
increased oxidative capacity
Metabolic transformation Glycolytic shift
Controversies
Inﬂammation Increased mononuclear cells and inﬂamma
Neurohormonal modulation Increased ACE activity (PAECs); down-regula
b1-adrenergic receptor (PASMCs)
ACE ¼ angiotensin-converting enzyme; AT-R1 ¼ angiotensin II receptor type 1; CM ¼ cardiomyocyte; PAEC
artery smooth muscle cells.susceptibility loci in PAH, identifying a susceptibility locus
to RHF will require larger sample sizes and matching for
degree according to ventricular dysfunction and afterload.
Several mechanisms contribute to maladaptive remodeling
of the pressure-overloaded ventricle, including increased
levels of reactive oxygen species, activation of myocardial
apoptotic pathways, and neurohormonal activation (e.g.,
adrenergic and angiotensin pathways) (80–82). Importantly,
cardiomyocyte hibernation and growth arrest contrast with
the resistance to apoptosis seen in the pulmonary vasculature
in PAH (Table 3, Fig. 3) (83).
When comparing the failing right and left ventricles, both
overlapping and varying expression in transcription factors,
messenger ribonucleic acid (RNA), and micro-RNA are
observed. The differences between the right and left ven-
tricles originate in part from their different embryologic
origins as well as their different mechanical boundary con-
ditions, the right ventricle being exposed to lower impedance
post-partum. From an embryologic point of view, the right
ventricle arises from the anterior heart ﬁeld, whereas the left
ventricle develops from the posterior heart ﬁeld (84). These
differences may explain the lack of Iroquois homeobox and
atrial natriuretic peptide expression in the normal right
ventricle (41,85,86). Although B-type natriuretic peptide is
also expressed in the failing right ventricle, the responsive-
ness to recombinant B-type natriuretic peptide may be
different in the failing right heart; whether this is due to
differences in loading conditions still requires further
study (87,88). As in the left ventricle, down-regulation of
fast alpha–myosin heavy chain and synchronous over-
expression of slow beta-isoform are also observed in the
pressure-overloaded right ventricle (89). The long-term
consequences of alpha–cardiac actin down-regulation on
contractile performance remain unknown (40). Because
alpha–myosin heavy chain requires larger amounts of aden-
osine triphosphate to generate force, a decreased alpha-
myosin/beta-myosin ratio may provide an energy-sparing
proﬁle that may have some advantages for long-termirculation in Patients With PAH:
Right Ventricle
eration
igration (PASMCs)
Growth arrest apoptosis (CMs)
Decreased capillary density
Increased interstitial ﬁbrosis
e, Decreased number abnormal shape and size,
decreased oxidative capacity
Glycolytic shift
tory cytokines Increased mast cells and inﬂammatory cytokines
tion of Impairment of AT-R1 signaling pathway
¼ pulmonary artery endothelial cell; PAH ¼ pulmonary arterial hypertension; PASMC ¼ pulmonary
Vonk-Noordegraaf et al. JACC Vol. 62, No. 25, Suppl D, 2013
The Right Ventricle in Pulmonary Hypertension December 24, 2013:D22–33
D28compensation of the right ventricle. Studies using microarray
gene chips have highlighted that 1 of the pathways that
appears to be more activated in the pressure-overloaded right
ventricle compared with the pressure overloaded left ventricle
is the Wnt pathway, which regulates glycogen synthase
kinase–3b activity, a serine/threonine protein kinase involved
in cell proliferation, migration, inﬂammation, glucose regu-
lation, and apoptosis (90). Chamber-speciﬁc expression of
phosphodiesterase type 5 in the pressure-overloaded right
ventricle has also been demonstrated in experimental and
human studies (91,92). Although most expressed micro-
RNA is similar in right and left heart failure, Reddy et al.
(93) showed that 4 micro-RNAs (34a, 28, 148a, and 93) are
upregulated in RHF/RV hypertrophy that are down-
regulated or unchanged in left heart failure/left ventricular
hypertrophy.
A change in myocardial metabolism is a prominent
feature of RHF. A switch from fatty acid oxidation to
glycolysis is presumably a protective response of the stressed
left heart, as carbohydrate metabolism requires less oxygen
amount than fatty acid oxidation (81). Decreased mito-
chondrial activity resulting in a switch from aerobic to
anaerobic metabolism might also be involved in the transi-
tion from compensated RV hypertrophy to maladaptive
remodeling (81). Insufﬁcient adaptation of the capillary
network and myocardial ischemia may also impair vascular
endothelial growth factor signaling and the hypertrophic
response (94). Increased rate of myocardial ﬁbrosis has been
reported in RV failure and may contribute to decreased
ventricular compliance (56,95).
Recent animal and human studies support a role of
inﬂammation in the pressure-overloaded right ventricle
(82,96). Studies by Watts et al. (97) have shown that
neutrophils are found in the RV myocardium early after an
acute increase in afterload, whereas macrophages may be
involved during progressive remodeling in the setting of
chronic pulmonary hypertension (97). Ongoing studies are
investigating the role of macrophages, T-regulatory cells, and
leukotriene in the development of RHF in patients with PAH.
Evaluation of Right Heart Size and Function:
From Resting Parameters to Dynamic Evaluation
The assessment of the right heart plays an essential
part in managing patients with PAH (98). Although echo-
cardiography is the mainstay in the evaluation of the right
heart in clinical practice, magnetic resonance imaging has
emerged as the most accurate method for evaluating RV
mass, RV volume, and RVEF. In addition, magnetic reso-
nance imaging offers the possibility to quantify regurgitant
volumes; delayed enhancement, a marker for focal scar
burden; myocardial strain; coronary perfusion; and pulmo-
nary pulsatility (98). Positron emission tomography is used
experimentally to assess RV and pulmonary metabolism and,
at specialized centers, for apoptosis imaging. Finally
conductance catheterization represents the gold-standardmethod for evaluating ventricular elastance, arterial ela-
stance, and ventriculoarterial coupling (5,43).
The American Society of Echocardiography guidelines
offer the most comprehensive review of normative echo-
cardiographic values of the right heart (99). The guideline
also highlights the need for future scaled echocardiographic
references for right heart dimensions as well as references
adjusted for age, sex, and race. Using a large cohort of 4,204
participants, the MESA (Multi-Ethnic Study of Athero-
sclerosis) investigators were able to develop these normative
equations for RV mass and systolic function on the basis of
age, sex, and race (100). Kawut et al. (100) demonstrated
that in general, younger age, male sex, and Hispanic
ethnicity are associated with higher RV mass, while older
age and female sex are associated with higher RVEF.
More recently, several investigators are working on deﬁning
dynamic right heart and pulmonary circulation measures.
These dynamic measures include themean pulmonary arterial
pressure–cardiac output slope as well as RV reserve, usually
deﬁned either as peak RVEF, peak stroke volume, or peak
cardiac index after exercise or pharmacological stress (101,102).
In controls, mean pulmonary arterial pressure–cardiac output
slope is usually <1.5 to 2.5 mm Hg$min/l, with older healthy
subjects having higher average slope values (22,103–113).
The committee wants to emphasize that the commonly
used indexes of RV systolic performance, such as RVEF
and tricuspid annular plane systolic excursion, are markers
of ventriculoarterial coupling rather than ventricular con-
tractility, which is increased in PAH (65). Another caveat the
committeememberswant to emphasize is that the reduction in
tricuspid annular plane systolic excursion after cardiac surgery
does not reﬂect corresponding changes in RVEF, because
annular plane motion is preferentially compromised (114).
Prediction of Outcomes in Patients With
Pulmonary Arterial Hypertension:
The Importance of the Right Heart
Outcome prediction in patients with PAH has been exten-
sively studied using large-cohort designs as well as in smaller
studies incorporating imaging parameters (7,8,10,12,13,
16–19,115–123). One consistent ﬁnding among studies is
that survival in PAH is closely related to RV adaptation to
the increased pressure overload. Hemodynamic studies have
demonstrated the predictive value of right atrial pressure and
cardiac index (7,14,117,118,124). Echocardiographic studies
have highlighted the predictive value of tricuspid annular
plane systolic excursion, RV myocardial performance in-
dex, atrial size, and pericardial effusion (10,12,13,17,125).
Magnetic resonance imaging studies have emphasized
the predictive value of stroke volume index, RVEF, and
indexed RV end-diastolic and end-systolic volumes
(18,115,116,122,126). Although delayed enhancement has
been associated with the severity of PAH, its independent
predictive value has not yet been proved (127). More recent
studies have shown the potential predictive value of RV strain
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D29(17). In terms of cardiac biomarkers, B-type natriuretic
peptide (and N-terminal B-type natriuretic peptide) and
troponin have been the most investigated cardiac biomarkers
in PAH and have both been found to be predictive
of outcomes (8,119,128–132). More recent studies are also
highlighting the role of high-sensitivity troponin assays in
PAH (129,130). Exercise testing has highlighted the value
of maximal oxygen consumption, right-to-left shunting,
maximal cardiac index with exercise, and the pulmonary
pressure–cardiac output slope (48,101).
Particularly with regard to the right heart, future outcome
studies in PAH will have 2 main objectives. First, studies are
needed to evaluate the role of novel imaging biomarkers,
such as right atrial function, ventricular strain, and
myocardial acceleration during isovolumic contraction, as
well as more recent reported biomarkers such as ST2 and
cystatin C. Second, multivariate studies will be needed to
validate a simpliﬁed predictive score incorporating imaging
parameters of the right heart.
Management of Right Heart Failure
From Pulmonary Vasodilation to
Targeted Right Ventricular Therapy
In addition to their effects on exercise capacity and
pulmonary vascular resistance, approved therapies for PAH
lead to reverse remodeling of the right heart. This is
mediated mainly through their vasodilatory or afterload-
reducing effects (133). Nagendran et al. (91) demonstrated
that the vasodilator sildenaﬁl may in addition have direct
inotropic effects. Whether this will translate into long-term
clinical beneﬁts compared with endothelin receptor blockers
still requires further study. Digoxin is the other oral into-
tropic agent occasionally used in symptomatic patients with
PAH; a small study of 17 patients has suggested the acute
hemodynamic effects of digoxin use in PAH (134).
Targeted right heart therapy has been the focus of recent
investigation in PAH. These usually fall into 2 categories,
the ﬁrst being the investigation of medication proved to be
beneﬁcial in left heart failure with decreased ejection fraction
and the second being the investigation of novel and poten-
tially speciﬁc targets of RHF. Because of the embryologic
and molecular differences between the right and left heart,
results for chronic left heart failure cannot be directly
extrapolated to RHF. Moreover, a pressure-overloaded
ventricle may respond differently than a non-pressure-
overloaded ventricle. Although recent experimental studies
have suggested beneﬁcial effects of carvedilol or bisoprolol
on ventricular remodeling in PAH, these beneﬁcial effects
may be mitigated in patients with severe PAH, in whom
contractile reserve is signiﬁcantly reduced (135,136). In fact,
a small clinical study by Provencher et al. (137) showed
detrimental effects of nonselective and selective beta-
blockade on exercise capacity in patients with portopulmo-
nary PAH. Clinical trials regarding the effects of resynch-
ronization therapy in patients with PAH are currentlyongoing, on the basis of early clinical and experimental
studies showing promising results (48,49). At this time, the
role of angiotensin-converting enzyme inhibitors, angio-
tensin or aldosterone blockade, myosin activators, implant-
able deﬁbrillator or destination RV assist device
implantation has not been comprehensively investigated in
patients with RHF and PAH.
For novel targeted RV drug therapy, the most promising
data are for metabolic modulation. On the basis of the
metabolic changes that are observed in the right heart and
pulmonary vasculature in patients with PAH, investigators
have at this time completed phase 1 and 2 clinical trials using
mitochondrial modulators such as dichloroacetate in PAH
(37,138). At this time, stem cell therapy or gene therapy
speciﬁcally targeting the right heart in PAH still needs to be
investigated.
In managing acute RHF in patients with PAH, the com-
mittee wants to emphasize 3 important aspects. First, volume
loading should be avoided in patients with evidence of in-
creased ﬁlling pressures (right atrial pressure>10 to 15mmHg)
because this can worsen ventricular performance by further
distending the right ventricle and increasing septal shift and
pericardial constraint through ventricular interdependence.
Second, every effort should be made to avoid the vicious
circle of hypotension and ventricular ischemia and further
hemodynamic compromise; this can include prompt car-
dioversion of atrial arrhythmias, early initiation of inotropic
or vasopressor support, and avoiding hypercapnia or
increased intrathoracic pressure, as well consideration of
extracorporeal membrane oxygenation when appropriate.
Third, it remains unclear which agent is the inotrope or
vasopressor of choice; the most commonly used agents
include dobutamine, dopamine, norepinephrine, and levo-
simendan (2,139–141).
Role of Right Heart Investigation
in the Development of Novel
Pulmonary Arterial Hypertension Therapy
Because medications affecting the pulmonary vasculature
may be detrimental to the right heart, the task force
recommends that any new drug developed for PAH should
therefore be experimentally tested for its effects on the
pressure-overloaded right heart. For example, imatinib,
which was shown to be promising for pulmonary vascular
remodeling, was shown to have potential cardiotoxic effects
(142,143). The variable effects can be explained by the fact
that although the remodeled lung in PAH vasculature is
characterized by angiogenesis, apoptosis resistance, and cell
proliferation, the failing right ventricle may be subject to
ischemia, capillary rarefaction, and cardiomyocyte apoptosis.
Future Directions
In this report, we have outlined the recent progress made in
understanding of the RHF syndrome, identifying key areas
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D30of future investigation. Areas of research priority are diverse
and include reﬁning the deﬁnition of normal right heart
structure and function; investigating novel genetic, epige-
netic, and molecular pathways of RHF; and developing
more effective management strategies for refractory RHF.
Furthermore, before proceeding to clinical trials, the effects
of any new medication should also be experimentally tested
on a pressure-overloaded right ventricle. Importantly, we
also recommend that clinical trials in PAH incorporate as
secondary outcome analysis parameters of right heart size
and function.
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